As expected, BRCA1-like and BRCA2-like HRD subtypes had better outcomes with standard treatment than the HRP subtypes (Fig. 4B), reflecting their sensitivity to platinum-based chemotherapy and PARP inhibitors. The gene discussed is BRCA2; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.